Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more

AbbVie confirmed a $10.9 billion acquisition of Apogee Therapeutics at $135.11 per share in cash, a 49% premium, driving the stock up 50% premarket. CRH also agreed to buy Arcosa for $8.5 billion, valuing it at $150 per share and sending the stock up more than 7%. Separately, Getty Images surged 150% on an OpenAI content agreement, while Micron rose 4.5% after two price-target hikes and Alphabet slipped nearly 2% on AI talent departures.

Analysis

The sharpest edge here is not the headline M&A premiums, but the signaling effect across sub-sectors: strategic buyers are effectively validating where they think growth is durable and where the cost of building internally is now higher than paying up. In biotech, that tends to pull forward bid expectations for names with clean phase-3 optionality and de-risked commercial paths, while making standalone platform stories without a near-term catalyst relatively less attractive. In materials, the deal suggests disciplined buyers still see fragmented, cash-generative assets as cheap enough to consolidate, which can re-rate adjacent names with similar margin profiles.

The AI/data-center complex is more nuanced. The move in memory names is likely a mix of inventory-cycle relief and the market beginning to price a tighter medium-term supply-demand balance from AI infra capex; that can sustain for several quarters if hyperscaler spend stays elevated. The optical-connectivity read-through matters more than the immediate upgrade: if the market migrates from copper to optical as the dominant narrative, suppliers with exposure to both can capture multiple expansion, while pure copper attach names risk becoming transition winners with an expiration date.

The GOOGL weakness is probably more about talent-flow optics than fundamental earnings risk, but the second-order issue is margin on AI commercialization: if top researchers keep migrating, the market may assign a higher probability to slower product velocity and more expensive retention. That creates a setup where the stock can drift lower on every incremental AI-leadership headline even if the core franchise is intact. Meanwhile, the Getty/OpenAI move is a reminder that incumbents with proprietary content can extract monetization from model distributors; the key question is whether this becomes a template for other content libraries, which would be supportive for asset-heavy media owners but pressure pure-scrape economics.

Key Decisions for Investors

• Long MU against WDC/STX for 1-3 months: prefer the best-operating-leverage memory name over HDD/flash peers if AI capex stays firm; target 10-15% relative outperformance, stop if memory guidance gets cut.
• Buy GOOGL dips only with defined-risk options: 1-2 month put spreads can hedge against continued AI-talent optics pressure while keeping upside if the move is purely sentiment-driven.
• Pair long GETY / short a broad media basket over 3-6 months: if licensing becomes the new model, content owners with negotiated distribution rights should re-rate faster than the average media complex.
• Take profits in APGE close to deal value, but use any wider-than-expected spread to express a low-risk merger arb long APGE / short market-neutral biotech basket until closing.
• Watch CRH post-close as a long-horizon comp re-rate candidate: if integration discipline looks credible, add on weakness rather than chase the gap, since strategic M&A can justify a higher multiple for the acquirer over 6-12 months.